"Regulatory activities continue to progress EBR made significant progress regarding key regulatory activities during the quarter. Following the Company’s update in November 2023, EBR is scheduled to submit the final module of its PMA submission in Q3 2024 and is targeting FDA approval in Q1 2025."
EBR Price at posting:
77.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)